Student Success Planning - PCG Education is a leading national provider of data solutions that promote student success. We combine K-12 consulting expertise with innovative technology and research-based methodology to help educators make informed decisions that lead to improved student outcomes.

Inhaled epoprostenol (iEPO) has been utilized to improve oxygenation in mechanically ventilated subjects with severe hypoxemia, but the evidence for iEPO via high-flow nasal cannula (HFNC) is rare.

Aug 8, 2022 · Study Question: What are the practice patterns and comparative effectiveness for inhaled nitric oxide (iNO) and inhaled epoprostenol (iEpo) in severe acute respiratory failure?

Inhaled pulmonary vasodilators, epoprostenol (iEPO) and nitric oxide (iNO), are used as adjunctive therapies for the treatment of refractory hypoxemia in patients with acute respiratory distress syndrome (ARDS).

Nov 17, 2021 · Introduction: Inhaled epoprostenol (iEpo) is a pulmonary vasodilator used to treat refractory respiratory failure, including that caused by Coronavirus 2019 (COVID-19) pneumonia.

The Institute for Energy Plant Operations purpose is to promote professionalism and safety of members through training, certification and validation of their credentials and skills.

Inhaled nitric oxide and inhaled epoprostenol (iEPO) are inhaled pulmonary vasodilators used for adjunctive management in patients with severe ARDS. This article describes the safe and effective use of iEPO in patients with refractory hypoxemia.

Feb 3, 2024 · Inhaled epoprostenol (iEPO) is an effective pulmonary vasodilator that can improve right ventricular performance. iEPO dilates the pulmonary blood vessels and decreases the RV afterload. iEPO can produce selective vasodilatory effect without inducing systemic side effects. iEPO can be administered to patients receiving high-flow nasal cannula ...

Pulmonary vasodilators, such as inhaled epoprostenol (iEPO), have been shown to improve PaO 2:FiO 2 (PF) and are used as adjunctive therapy. Objective: To identify the positive response rate and variables associated with response to iEPO in adults with ARDS.

Results: Eighty patients with laboratory confirmed SARS-CoV2 received iEpo while mechanically ventilated and had PaO 2 /FiO 2 measured before and after. The median PaO 2 /FiO 2 prior to receiving iEpo was 92 mmHg and interquartile range (74 - 122).